These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11071803)

  • 1. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
    Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
    Eur Heart J; 2000 Dec; 21(23):1967-78. PubMed ID: 11071803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
    Cleland JG; Thygesen K; Uretsky BF; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L;
    Eur Heart J; 2001 Sep; 22(17):1601-12. PubMed ID: 11492990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
    Davidson NC; Coutie WJ; Webb DJ; Struthers AD
    Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ATLAS study: low-dose versus high-dose lisinopril in heart failure.
    Horowitz JD
    Int J Clin Pract Suppl; 1999 Apr; 100():15-6. PubMed ID: 10658293
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin.
    Guazzi M; Brambilla R; Reina G; Tumminello G; Guazzi MD
    Arch Intern Med; 2003 Jul; 163(13):1574-9. PubMed ID: 12860580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
    Nicklas JM; Cohn JN; Pitt B
    J Card Fail; 2000 Jun; 6(2):165-8. PubMed ID: 10908091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
    Cleland JG; Armstrong P; Horowitz JD; Massie B; Packer M; Poole-Wilson PA; Rydén L
    Eur J Heart Fail; 1999 Mar; 1(1):73-9. PubMed ID: 10937983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
    Chen YT; Wang Y; Radford MJ; Krumholz HM
    Am Heart J; 2001 Mar; 141(3):410-7. PubMed ID: 11231438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
    Cleland JG; Tendera M; Adamus J; Freemantle N; Polonski L; Taylor J;
    Eur Heart J; 2006 Oct; 27(19):2338-45. PubMed ID: 16963472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heart failure: critical patients].
    Fabbri G; Gorini M; Maggioni AP; Oliva F;
    G Ital Cardiol (Rome); 2007 Sep; 8(9):568-73. PubMed ID: 17972426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
    Cleland JG
    Int J Clin Pract Suppl; 1999 Apr; 100():19-20. PubMed ID: 10658295
    [No Abstract]   [Full Text] [Related]  

  • 20. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
    Kazi D; Deswal A
    Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.